Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-060640
Filing Date
2026-05-22
Accepted
2026-05-22 16:55:07
Documents
53
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0291215-10q_lakewood.htm   iXBRL 10-Q 510798
2 CERTIFICATION ea029121501ex31-1.htm EX-31.1 10958
3 CERTIFICATION ea029121501ex31-2.htm EX-31.2 10500
4 CERTIFICATION ea029121501ex32-1.htm EX-32.1 4511
5 CERTIFICATION ea029121501ex32-2.htm EX-32.2 4108
  Complete submission text file 0001213900-26-060640.txt   3595179

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE labt-20260331.xsd EX-101.SCH 33820
7 XBRL CALCULATION FILE labt-20260331_cal.xml EX-101.CAL 21954
8 XBRL DEFINITION FILE labt-20260331_def.xml EX-101.DEF 160782
9 XBRL LABEL FILE labt-20260331_lab.xml EX-101.LAB 282343
10 XBRL PRESENTATION FILE labt-20260331_pre.xml EX-101.PRE 171342
57 EXTRACTED XBRL INSTANCE DOCUMENT ea0291215-10q_lakewood_htm.xml XML 296153
Mailing Address 8031 COOPER CREEK BLVD. SUITE 103 UNIVERSITY PARK FL 34201
Business Address 8031 COOPER CREEK BLVD. SUITE 103 UNIVERSITY PARK FL 34201 9412252515
Lakewood-Amedex Biotherapeutics Inc. (Filer) CIK: 0002079272 (see all company filings)

EIN.: 205274304 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43239 | Film No.: 261014805
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)